GenoFocus Past Earnings Performance
Past criteria checks 0/6
GenoFocus's earnings have been declining at an average annual rate of -20.2%, while the Chemicals industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 17% per year.
Key information
-20.2%
Earnings growth rate
-19.1%
EPS growth rate
| Chemicals Industry Growth | 13.9% |
| Revenue growth rate | 17.0% |
| Return on equity | -2.5% |
| Net Margin | -10.9% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How GenoFocus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 27,008 | -2,950 | 4,025 | 11,608 |
| 30 Sep 23 | 25,340 | -15,879 | 5,882 | 13,050 |
| 30 Jun 23 | 25,467 | -13,668 | 4,356 | 11,891 |
| 31 Mar 23 | 27,827 | -13,706 | 4,476 | 12,147 |
| 31 Dec 22 | 27,802 | -12,968 | 4,230 | 11,681 |
| 30 Sep 22 | 27,274 | -8,837 | 4,183 | 11,541 |
| 30 Jun 22 | 27,140 | -8,641 | 3,716 | 11,457 |
| 31 Mar 22 | 26,427 | -8,222 | 3,360 | 11,570 |
| 31 Dec 21 | 25,874 | -6,817 | 2,913 | 10,413 |
| 30 Sep 21 | 22,921 | -10,312 | 2,828 | 10,370 |
| 30 Jun 21 | 20,533 | -10,298 | 2,567 | 9,810 |
| 31 Mar 21 | 19,258 | -13,035 | 2,451 | 8,274 |
| 31 Dec 20 | 18,769 | -12,217 | 2,364 | 8,025 |
| 30 Sep 20 | 18,853 | -5,142 | 2,290 | 5,922 |
| 30 Jun 20 | 17,807 | -5,729 | 2,181 | 5,149 |
| 31 Mar 20 | 16,287 | -5,907 | 2,189 | 4,983 |
| 31 Dec 19 | 14,942 | -5,759 | 2,151 | 4,261 |
| 30 Sep 19 | 12,878 | -5,952 | 1,975 | 3,401 |
| 30 Jun 19 | 13,169 | -3,427 | 1,928 | 2,144 |
| 31 Mar 19 | 12,388 | -3,020 | 1,767 | 1,202 |
| 31 Dec 18 | 11,518 | -2,323 | 1,808 | 899 |
| 30 Sep 18 | 11,592 | -43 | 1,649 | 671 |
| 30 Jun 18 | 11,138 | 433 | 1,645 | 537 |
| 31 Mar 18 | 11,685 | 1,457 | 1,772 | 359 |
| 31 Dec 17 | 11,506 | 1,411 | 1,594 | 352 |
| 30 Sep 17 | 10,922 | 2,044 | 1,589 | 295 |
| 30 Jun 17 | 9,895 | 2,214 | 1,532 | 360 |
| 31 Mar 17 | 8,054 | 2,123 | 1,302 | 331 |
| 31 Dec 16 | 7,029 | 1,615 | 1,265 | 265 |
| 30 Sep 16 | 6,562 | 874 | 1,188 | 247 |
| 30 Jun 16 | 6,461 | 1,243 | 1,146 | 124 |
| 31 Mar 16 | 6,654 | 1,187 | 1,071 | 108 |
| 31 Dec 15 | 6,640 | 1,211 | 978 | 136 |
| 30 Sep 15 | 8,410 | 3,192 | 910 | 203 |
| 30 Jun 15 | 7,796 | 2,569 | 858 | 208 |
| 31 Mar 15 | 6,798 | 2,313 | 860 | 233 |
| 31 Dec 14 | 6,148 | 2,182 | 817 | 244 |
| 31 Dec 13 | 2,404 | 147 | 444 | 465 |
Quality Earnings: A187420 is currently unprofitable.
Growing Profit Margin: A187420 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A187420 is unprofitable, and losses have increased over the past 5 years at a rate of 20.2% per year.
Accelerating Growth: Unable to compare A187420's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A187420 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-15.5%).
Return on Equity
High ROE: A187420 has a negative Return on Equity (-2.45%), as it is currently unprofitable.